Valuation: CytRx Corporation

Market Cap 5.45K 4.84K 4.52K 4.12K 7.76K 524K 7.87K 54.72K 21.18K 267K 20.45K 20K 858K P/E 2023
1.91x
P/E 2024 -0.52x
Enterprise Value -754K -670K -627K -571K -1.07M -72.62M -1.09M -7.58M -2.93M -36.99M -2.83M -2.77M -119M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
Change 5-day change 1-year change 3-year change Capi.($)
+5.24%+2.89% - - 0
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.61%+0.81%+27.25%+82.72% 59.26B
-2.54%-1.65%+4.86%+31.72% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.85%+2.64%+29.28%+22.38% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.29%-0.52%+53.17%+154.23% 43.6B
Weighted average by Cap. -0.36%-0.32%+58.48%+146.08%

Financials

2023 2024
Net sales - -
Net income 400K 356K 333K 303K 571K 38.55M 578K 4.02M 1.56M 19.64M 1.5M 1.47M 63.07M -1.59M -1.41M -1.32M -1.2M -2.27M -153M -2.3M -15.97M -6.18M -77.95M -5.97M -5.84M -250M
Net Debt -2.04M -1.81M -1.69M -1.54M -2.9M -196M -2.94M -20.46M -7.92M -99.86M -7.65M -7.48M -321M -760K -675K -631K -575K -1.08M -73.15M -1.1M -7.63M -2.96M -37.25M -2.85M -2.79M -120M
Logo CytRx Corporation
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.
Employees
-